Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis
Objectives Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment‐related toxicities. We aimed to synthesise data on th...
Gespeichert in:
Veröffentlicht in: | European journal of haematology 2016-11, Vol.97 (5), p.416-429 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 429 |
---|---|
container_issue | 5 |
container_start_page | 416 |
container_title | European journal of haematology |
container_volume | 97 |
creator | Ramsenthaler, Christina Kane, Pauline Gao, Wei Siegert, Richard J. Edmonds, Polly M. Schey, Stephen A. Higginson, Irene J. |
description | Objectives
Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment‐related toxicities. We aimed to synthesise data on the prevalence of symptoms in patients with MM.
Methods
A systematic database and grey literature search were conducted in six databases. Random‐effects meta‐analysis with inverse variance weighting to pool prevalence data was performed.
Results
Thirty‐six studies were included of which 34 studies (N = 3023) provided data for meta‐analysis. Twenty‐seven distinct symptoms were reported, with the majority of studies focusing on pain (n = 27), fatigue (n = 19) and problems with functioning (n = 15). The most prevalent symptoms were fatigue (98.8%, 95% CI 98.1–99.2%), pain (73%, 39.9–91.7), constipation (65.2%, 22.9–92.2) and tingling in the hands/feet with 53.4% (0.4–99.7). The most common problems were decreased physical functioning (98.9%, 98.2–99.3), decreased cognitive functioning (80.2%, 40–96.1) and financial difficulties (78.4%, 39.1–95.4). These problems were present in newly diagnosed to advanced disease stage.
Conclusions
Optimal quality of life and good symptom management in this incurable disease can only be achieved by routinely assessing symptoms throughout the disease trajectory. |
doi_str_mv | 10.1111/ejh.12790 |
format | Article |
fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_ejh_12790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EJH12790</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3980-a52ffb15852b723419450ae75ad1ba03955e159e94545c3ee1c4d2b8bae8553f3</originalsourceid><addsrcrecordid>eNp1kD1PwzAQQC0EoqUw8AeQV4a0thMnMRtCpQWVT_ExWk5yUV3iJIpTSv49htBu3HLS6d0bHkKnlIypmwmslmPKIkH20JCGhHgkJGIfDYkgzAuCgA7QkbUrQggTNDpEAxZxFgciHCL52MCnKqBMAVc5tp2p28pYrEtcq1ZD2Vq80e0Sm3XR6roAbDooKqMusHK0bcE4LMXOomGDVZlhA63yVKmKzmp7jA5yVVg4-dsj9Ho9fbmae4uH2c3V5cJLfRETT3GW5wnlMWdJxPyAioATBRFXGU0U8QXnQLkAdw546gPQNMhYEicKYs793B-h896bNpW1DeSybrRRTScpkT-RpIskfyM59qxn63ViINuR2yoOmPTARhfQ_W-S09v5Vun1H9oV-dp9qOZDhpEfcfl-P5OCvYVPzyGVd_43kCGA9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ramsenthaler, Christina ; Kane, Pauline ; Gao, Wei ; Siegert, Richard J. ; Edmonds, Polly M. ; Schey, Stephen A. ; Higginson, Irene J.</creator><creatorcontrib>Ramsenthaler, Christina ; Kane, Pauline ; Gao, Wei ; Siegert, Richard J. ; Edmonds, Polly M. ; Schey, Stephen A. ; Higginson, Irene J.</creatorcontrib><description>Objectives
Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment‐related toxicities. We aimed to synthesise data on the prevalence of symptoms in patients with MM.
Methods
A systematic database and grey literature search were conducted in six databases. Random‐effects meta‐analysis with inverse variance weighting to pool prevalence data was performed.
Results
Thirty‐six studies were included of which 34 studies (N = 3023) provided data for meta‐analysis. Twenty‐seven distinct symptoms were reported, with the majority of studies focusing on pain (n = 27), fatigue (n = 19) and problems with functioning (n = 15). The most prevalent symptoms were fatigue (98.8%, 95% CI 98.1–99.2%), pain (73%, 39.9–91.7), constipation (65.2%, 22.9–92.2) and tingling in the hands/feet with 53.4% (0.4–99.7). The most common problems were decreased physical functioning (98.9%, 98.2–99.3), decreased cognitive functioning (80.2%, 40–96.1) and financial difficulties (78.4%, 39.1–95.4). These problems were present in newly diagnosed to advanced disease stage.
Conclusions
Optimal quality of life and good symptom management in this incurable disease can only be achieved by routinely assessing symptoms throughout the disease trajectory.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.12790</identifier><identifier>PMID: 27528496</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Humans ; multiple myeloma ; Multiple Myeloma - diagnosis ; Multiple Myeloma - epidemiology ; Neoplasm Staging ; Prevalence ; Quality of Life ; signs and symptoms ; Symptom Assessment ; symptom burden ; systematic review</subject><ispartof>European journal of haematology, 2016-11, Vol.97 (5), p.416-429</ispartof><rights>2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3980-a52ffb15852b723419450ae75ad1ba03955e159e94545c3ee1c4d2b8bae8553f3</citedby><cites>FETCH-LOGICAL-c3980-a52ffb15852b723419450ae75ad1ba03955e159e94545c3ee1c4d2b8bae8553f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.12790$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.12790$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27528496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramsenthaler, Christina</creatorcontrib><creatorcontrib>Kane, Pauline</creatorcontrib><creatorcontrib>Gao, Wei</creatorcontrib><creatorcontrib>Siegert, Richard J.</creatorcontrib><creatorcontrib>Edmonds, Polly M.</creatorcontrib><creatorcontrib>Schey, Stephen A.</creatorcontrib><creatorcontrib>Higginson, Irene J.</creatorcontrib><title>Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Objectives
Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment‐related toxicities. We aimed to synthesise data on the prevalence of symptoms in patients with MM.
Methods
A systematic database and grey literature search were conducted in six databases. Random‐effects meta‐analysis with inverse variance weighting to pool prevalence data was performed.
Results
Thirty‐six studies were included of which 34 studies (N = 3023) provided data for meta‐analysis. Twenty‐seven distinct symptoms were reported, with the majority of studies focusing on pain (n = 27), fatigue (n = 19) and problems with functioning (n = 15). The most prevalent symptoms were fatigue (98.8%, 95% CI 98.1–99.2%), pain (73%, 39.9–91.7), constipation (65.2%, 22.9–92.2) and tingling in the hands/feet with 53.4% (0.4–99.7). The most common problems were decreased physical functioning (98.9%, 98.2–99.3), decreased cognitive functioning (80.2%, 40–96.1) and financial difficulties (78.4%, 39.1–95.4). These problems were present in newly diagnosed to advanced disease stage.
Conclusions
Optimal quality of life and good symptom management in this incurable disease can only be achieved by routinely assessing symptoms throughout the disease trajectory.</description><subject>Humans</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - diagnosis</subject><subject>Multiple Myeloma - epidemiology</subject><subject>Neoplasm Staging</subject><subject>Prevalence</subject><subject>Quality of Life</subject><subject>signs and symptoms</subject><subject>Symptom Assessment</subject><subject>symptom burden</subject><subject>systematic review</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD1PwzAQQC0EoqUw8AeQV4a0thMnMRtCpQWVT_ExWk5yUV3iJIpTSv49htBu3HLS6d0bHkKnlIypmwmslmPKIkH20JCGhHgkJGIfDYkgzAuCgA7QkbUrQggTNDpEAxZxFgciHCL52MCnKqBMAVc5tp2p28pYrEtcq1ZD2Vq80e0Sm3XR6roAbDooKqMusHK0bcE4LMXOomGDVZlhA63yVKmKzmp7jA5yVVg4-dsj9Ho9fbmae4uH2c3V5cJLfRETT3GW5wnlMWdJxPyAioATBRFXGU0U8QXnQLkAdw546gPQNMhYEicKYs793B-h896bNpW1DeSybrRRTScpkT-RpIskfyM59qxn63ViINuR2yoOmPTARhfQ_W-S09v5Vun1H9oV-dp9qOZDhpEfcfl-P5OCvYVPzyGVd_43kCGA9w</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Ramsenthaler, Christina</creator><creator>Kane, Pauline</creator><creator>Gao, Wei</creator><creator>Siegert, Richard J.</creator><creator>Edmonds, Polly M.</creator><creator>Schey, Stephen A.</creator><creator>Higginson, Irene J.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201611</creationdate><title>Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis</title><author>Ramsenthaler, Christina ; Kane, Pauline ; Gao, Wei ; Siegert, Richard J. ; Edmonds, Polly M. ; Schey, Stephen A. ; Higginson, Irene J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3980-a52ffb15852b723419450ae75ad1ba03955e159e94545c3ee1c4d2b8bae8553f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Humans</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - diagnosis</topic><topic>Multiple Myeloma - epidemiology</topic><topic>Neoplasm Staging</topic><topic>Prevalence</topic><topic>Quality of Life</topic><topic>signs and symptoms</topic><topic>Symptom Assessment</topic><topic>symptom burden</topic><topic>systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramsenthaler, Christina</creatorcontrib><creatorcontrib>Kane, Pauline</creatorcontrib><creatorcontrib>Gao, Wei</creatorcontrib><creatorcontrib>Siegert, Richard J.</creatorcontrib><creatorcontrib>Edmonds, Polly M.</creatorcontrib><creatorcontrib>Schey, Stephen A.</creatorcontrib><creatorcontrib>Higginson, Irene J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramsenthaler, Christina</au><au>Kane, Pauline</au><au>Gao, Wei</au><au>Siegert, Richard J.</au><au>Edmonds, Polly M.</au><au>Schey, Stephen A.</au><au>Higginson, Irene J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2016-11</date><risdate>2016</risdate><volume>97</volume><issue>5</issue><spage>416</spage><epage>429</epage><pages>416-429</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Objectives
Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment‐related toxicities. We aimed to synthesise data on the prevalence of symptoms in patients with MM.
Methods
A systematic database and grey literature search were conducted in six databases. Random‐effects meta‐analysis with inverse variance weighting to pool prevalence data was performed.
Results
Thirty‐six studies were included of which 34 studies (N = 3023) provided data for meta‐analysis. Twenty‐seven distinct symptoms were reported, with the majority of studies focusing on pain (n = 27), fatigue (n = 19) and problems with functioning (n = 15). The most prevalent symptoms were fatigue (98.8%, 95% CI 98.1–99.2%), pain (73%, 39.9–91.7), constipation (65.2%, 22.9–92.2) and tingling in the hands/feet with 53.4% (0.4–99.7). The most common problems were decreased physical functioning (98.9%, 98.2–99.3), decreased cognitive functioning (80.2%, 40–96.1) and financial difficulties (78.4%, 39.1–95.4). These problems were present in newly diagnosed to advanced disease stage.
Conclusions
Optimal quality of life and good symptom management in this incurable disease can only be achieved by routinely assessing symptoms throughout the disease trajectory.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>27528496</pmid><doi>10.1111/ejh.12790</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0902-4441 |
ispartof | European journal of haematology, 2016-11, Vol.97 (5), p.416-429 |
issn | 0902-4441 1600-0609 |
language | eng |
recordid | cdi_crossref_primary_10_1111_ejh_12790 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Humans multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - epidemiology Neoplasm Staging Prevalence Quality of Life signs and symptoms Symptom Assessment symptom burden systematic review |
title | Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A03%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20symptoms%20in%20patients%20with%20multiple%20myeloma:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=European%20journal%20of%20haematology&rft.au=Ramsenthaler,%20Christina&rft.date=2016-11&rft.volume=97&rft.issue=5&rft.spage=416&rft.epage=429&rft.pages=416-429&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.12790&rft_dat=%3Cwiley_cross%3EEJH12790%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27528496&rfr_iscdi=true |